Knowing stock market today at a glance

Novo Nordisk Soars 2.72% on Wegovy Sales Surge

Mover TrackerThursday, May 1, 2025 6:43 am ET

1min read

On May 1, 2025, Novo Nordisk's stock rose by 2.72% in pre-market trading, reflecting positive market sentiment towards the company's recent developments and financial performance.

Novo Nordisk's CEO, Lars Fruergaard Jorgensen, recently delivered a speech at the 2025 Norwegian Central Bank Investment Management Conference, emphasizing the company's mission to address unmet medical needs and its focus on a narrow but critical technological field. Jorgensen highlighted the company's strategic framework, which involves concentrating on a few core technologies and disease areas, and expanding into related fields such as obesity, cardiovascular diseases, and Alzheimer's disease through "adjacency thinking."

Jorgensen also discussed the company's "innovation grid," which focuses on a few key technologies and disease areas, allowing novo nordisk to build deep expertise and achieve global leadership in these fields. He mentioned that many of the company's breakthrough products originated from the persistence of individual scientists who challenged conventional wisdom. For example, the development of GLP-1 drugs, which have shown promise in treating obesity and cardiovascular diseases, was initially met with skepticism within the company.

Novo Nordisk's recent financial performance has been strong, with its flagship weight loss drug, Wegovy, reporting significant sales growth. The company's third-quarter financial results showed a 79% year-over-year increase in Wegovy's sales, driven by growing insurance coverage and increased demand in the U.S. market. This performance has led Novo Nordisk to raise its full-year guidance, projecting a 23-27% increase in sales and a 21-27% increase in operating profit for 2024.

In addition to Wegovy, Novo Nordisk is developing several other promising weight loss drugs, including CagriSema, a combination drug that includes semaglutide and cagrilintide. The company has also submitted an application to the FDA for a 25mg oral version of semaglutide, which has shown promising results in clinical trials. This oral version is expected to provide a more convenient treatment option for patients, potentially expanding the market for weight loss drugs.

Disclaimer: the above is a summary showing certain market information. AInvest is not responsible for any data errors, omissions or other information that may be displayed incorrectly as the data is derived from a third party source. Communications displaying market prices, data and other information available in this post are meant for informational purposes only and are not intended as an offer or solicitation for the purchase or sale of any security. Please do your own research when investing. All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Keep in mind that while diversification may help spread risk, it does not assure a profit, or protect against loss in a down market.